ACADIA Pharmaceuticals Inc. — FY 2011 Form 10-K
Reporting period: Fiscal year ended December 31, 2011. The filing also reports fourth-quarter results. ACADIA is a clinical-stage biopharmaceutical company developing small-molecule therapies for neurological and central nervous system disorders; it had no approved products or product-sale revenue.
Financial performance and liquidity
| Metric | FY 2011 | FY 2010 |
|---|---|---|
| Collaborative revenue | $2.1 million | $42.1 million |
| Research and development | $17.3 million | $20.6 million |
| General and administrative | $7.6 million | $6.5 million |
| Operating income (loss) | ($22.9 million) | $15.1 million |
| Net income (loss) | ($22.8 million) | $15.1 million |
| Net income (loss) per share, diluted | ($0.44) | $0.39 |
| Cash, cash equivalents and investments at year-end | $31.0 million | $37.1 million |
| Working capital at year-end | $25.8 million | $31.9 million |
- FY 2011 operating cash use was $19.9 million, versus $10.7 million in 2010. Investing activities provided $6.0 million, principally as investment maturities exceeded purchases; financing activities provided $13.9 million, mainly from an equity financing.
- Year-end debt was minimal: $32,000 current debt and no long-term debt. Total liabilities were $8.8 million.
- Fourth-quarter 2011 revenue was $588,000; net loss was $5.3 million, or $0.10 per share.
- Profitability and operating margins are not meaningful indicators here: revenue consisted of collaborations, while the company remained loss-making and had no product sales.
Material changes and unusual items
- Revenue fell sharply from 2010 because ACADIA recognized $39.5 million of Biovail collaboration revenue that year, including $34.7 million in Q4, when the parties ended the collaboration and ACADIA regained all pimavanserin rights. The 2010 profit was therefore not representative of recurring operations.
- R&D expense declined 16% year over year, largely due to lower pimavanserin Phase III and other external service costs. Management expected R&D spending to increase as development continued.
- G&A increased, including a net $1.1 million charge related to terminating the Swedish facility lease. The settlement included a $690,000 cash payment and 782,339 shares.
- In January 2011, the company raised $13.9 million net by issuing 12.6 million shares and warrants exercisable for approximately 4.4 million additional shares. Year-end shares outstanding rose to 52.9 million from 39.4 million.
- Revenue was concentrated among collaborators and grant funding: Allergan accounted for 52% of 2011 revenue, Meiji Seika Pharma 25%, and The Michael J. Fox Foundation 13%.
Business outlook, risks and contingencies
- Pimavanserin was the lead asset, in Phase III development for Parkinson’s disease psychosis. ACADIA expected top-line results from the pivotal -020 study near the end of Q3 2012; if successful, it would be the first of two required pivotal trials. The company held worldwide rights and was responsible for the program after ending its Biovail partnership.
- Management expected existing cash, investments and anticipated collaboration payments to fund operations at least into Q2 2013, but stated that significant additional financing would be needed. It warned that unavailable or unfavorable financing could force delays, program reductions, or licensing of rights on less favorable terms.
- The company expected net losses for several years and no product revenue for at least several years. No specific earnings or revenue guidance was provided.
- Key risks include clinical-trial failure or delay, including the prior Phase III -012 study that missed its primary endpoint; regulatory approval uncertainty; reliance on collaborators and contract research/manufacturing organizations; concentrated collaboration revenue; and dilution or reduced development scope if financing is unavailable. Allergan was seeking a partner for further development of the chronic-pain program.
- Other commitments included up to approximately $6.3 million of future contract research and external-service work, generally stoppable on short notice, and up to $10.5 million of contingent Ipsen milestone payments. Operating lease commitments totaled $755,000, all due within one year.
- The independent auditor issued an unqualified opinion, and management and the auditor reported effective internal control over financial reporting as of year-end.
Important facts for investors to verify
- Whether the -020 trial met its efficacy and safety endpoints, and the timing and requirements for a second pivotal trial.
- Current cash burn, collaboration receipts, and financing runway versus the stated Q2 2013 estimate.
- Potential dilution from outstanding warrants, options, and any further equity financing.
- Progress and funding responsibility for partner programs, particularly Allergan’s chronic-pain program and Meiji’s AM-831 collaboration.
- Whether the 2010 Biovail revenue recognition and the 2011 Swedish lease termination charges are clearly separated from recurring performance in comparisons.